| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 63 | 2022 | 348 | 14.270 |
Why?
|
| Diabetes Mellitus, Type 2 | 48 | 2022 | 755 | 7.890 |
Why?
|
| Pregnancy | 83 | 2023 | 1535 | 4.580 |
Why?
|
| Pregnancy Complications | 11 | 2020 | 203 | 3.300 |
Why?
|
| Female | 150 | 2023 | 12729 | 3.280 |
Why?
|
| Blood Glucose | 30 | 2022 | 348 | 3.250 |
Why?
|
| Life Style | 13 | 2021 | 332 | 3.230 |
Why?
|
| Prenatal Care | 8 | 2021 | 129 | 3.140 |
Why?
|
| Weight Gain | 13 | 2018 | 175 | 3.130 |
Why?
|
| Humans | 161 | 2023 | 17707 | 2.860 |
Why?
|
| Obesity | 21 | 2023 | 841 | 2.800 |
Why?
|
| Adult | 98 | 2022 | 7658 | 2.760 |
Why?
|
| Diabetes Mellitus | 22 | 2019 | 483 | 2.690 |
Why?
|
| Ethnic Groups | 15 | 2020 | 474 | 2.640 |
Why?
|
| Body Mass Index | 28 | 2022 | 970 | 2.410 |
Why?
|
| Hypoglycemic Agents | 18 | 2022 | 271 | 2.360 |
Why?
|
| Exercise | 12 | 2022 | 496 | 2.200 |
Why?
|
| Overweight | 10 | 2022 | 270 | 2.180 |
Why?
|
| Thiazolidinediones | 9 | 2015 | 52 | 2.080 |
Why?
|
| Weight Loss | 8 | 2020 | 305 | 1.970 |
Why?
|
| Health Promotion | 7 | 2020 | 280 | 1.950 |
Why?
|
| Postpartum Period | 7 | 2022 | 99 | 1.940 |
Why?
|
| California | 52 | 2020 | 2327 | 1.860 |
Why?
|
| Weight Reduction Programs | 3 | 2020 | 52 | 1.810 |
Why?
|
| Young Adult | 31 | 2021 | 2450 | 1.690 |
Why?
|
| Cohort Studies | 45 | 2023 | 2589 | 1.620 |
Why?
|
| Risk Factors | 46 | 2021 | 3367 | 1.580 |
Why?
|
| Urinary Bladder Neoplasms | 5 | 2015 | 58 | 1.530 |
Why?
|
| Middle Aged | 75 | 2020 | 7976 | 1.480 |
Why?
|
| Telemedicine | 3 | 2022 | 185 | 1.470 |
Why?
|
| Risk Reduction Behavior | 5 | 2020 | 108 | 1.370 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2020 | 121 | 1.360 |
Why?
|
| Fetal Macrosomia | 5 | 2017 | 27 | 1.340 |
Why?
|
| Infant, Newborn | 20 | 2022 | 857 | 1.260 |
Why?
|
| Prostatic Neoplasms | 4 | 2015 | 262 | 1.250 |
Why?
|
| Glucose Intolerance | 7 | 2015 | 46 | 1.240 |
Why?
|
| Health Status Disparities | 4 | 2019 | 147 | 1.190 |
Why?
|
| Male | 70 | 2023 | 10094 | 1.180 |
Why?
|
| Continental Population Groups | 11 | 2020 | 301 | 1.160 |
Why?
|
| Adolescent | 33 | 2023 | 3671 | 1.120 |
Why?
|
| Electronic Health Records | 5 | 2018 | 694 | 1.070 |
Why?
|
| Hispanic Americans | 9 | 2017 | 397 | 1.060 |
Why?
|
| Prevalence | 18 | 2020 | 882 | 1.000 |
Why?
|
| Glucose Tolerance Test | 12 | 2022 | 113 | 1.000 |
Why?
|
| Pediatric Obesity | 4 | 2022 | 85 | 1.000 |
Why?
|
| Polycystic Ovary Syndrome | 3 | 2017 | 19 | 0.930 |
Why?
|
| Diabetes Complications | 11 | 2013 | 113 | 0.920 |
Why?
|
| Premature Birth | 3 | 2022 | 141 | 0.910 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2014 | 23 | 0.910 |
Why?
|
| Pancreatic Neoplasms | 2 | 2015 | 67 | 0.890 |
Why?
|
| Preconception Care | 3 | 2021 | 44 | 0.890 |
Why?
|
| Prospective Studies | 20 | 2023 | 1287 | 0.880 |
Why?
|
| Aged | 44 | 2019 | 6150 | 0.860 |
Why?
|
| Cardiovascular Diseases | 6 | 2017 | 596 | 0.850 |
Why?
|
| Healthy Lifestyle | 2 | 2020 | 16 | 0.820 |
Why?
|
| Triclosan | 1 | 2022 | 4 | 0.820 |
Why?
|
| Case-Control Studies | 17 | 2022 | 1117 | 0.820 |
Why?
|
| Longitudinal Studies | 15 | 2023 | 717 | 0.790 |
Why?
|
| Pregnancy Trimester, First | 3 | 2020 | 40 | 0.790 |
Why?
|
| Insulin Resistance | 6 | 2019 | 137 | 0.750 |
Why?
|
| Databases, Factual | 4 | 2019 | 311 | 0.720 |
Why?
|
| Translational Medical Research | 2 | 2020 | 34 | 0.720 |
Why?
|
| Odds Ratio | 11 | 2017 | 670 | 0.720 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 1218 | 0.690 |
Why?
|
| Pregnancy Outcome | 5 | 2022 | 162 | 0.680 |
Why?
|
| Mentoring | 2 | 2017 | 26 | 0.660 |
Why?
|
| Breast Feeding | 5 | 2014 | 137 | 0.650 |
Why?
|
| Prenatal Exposure Delayed Effects | 7 | 2023 | 167 | 0.650 |
Why?
|
| Social Values | 1 | 2019 | 14 | 0.640 |
Why?
|
| Pregnancy in Diabetics | 3 | 2016 | 21 | 0.630 |
Why?
|
| Asian Americans | 6 | 2017 | 175 | 0.620 |
Why?
|
| Insulin | 13 | 2022 | 213 | 0.620 |
Why?
|
| Behavior Therapy | 3 | 2015 | 144 | 0.620 |
Why?
|
| Cross-Sectional Studies | 19 | 2022 | 1322 | 0.610 |
Why?
|
| Hypoglycemia | 4 | 2006 | 49 | 0.600 |
Why?
|
| Diabetic Angiopathies | 5 | 2007 | 35 | 0.590 |
Why?
|
| Precision Medicine | 1 | 2018 | 28 | 0.580 |
Why?
|
| Child | 17 | 2023 | 2481 | 0.580 |
Why?
|
| Telephone | 5 | 2017 | 161 | 0.570 |
Why?
|
| Incidence | 13 | 2020 | 1269 | 0.570 |
Why?
|
| Logistic Models | 14 | 2016 | 918 | 0.570 |
Why?
|
| Health Education | 2 | 2017 | 110 | 0.560 |
Why?
|
| Hypertension | 6 | 2011 | 498 | 0.550 |
Why?
|
| United States | 14 | 2023 | 3914 | 0.540 |
Why?
|
| European Continental Ancestry Group | 7 | 2017 | 523 | 0.540 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2022 | 531 | 0.540 |
Why?
|
| Surveys and Questionnaires | 7 | 2023 | 1322 | 0.530 |
Why?
|
| Estrogen Replacement Therapy | 4 | 2003 | 99 | 0.530 |
Why?
|
| Health Maintenance Organizations | 7 | 2013 | 414 | 0.520 |
Why?
|
| Risk | 10 | 2017 | 517 | 0.520 |
Why?
|
| Patient Participation | 1 | 2017 | 132 | 0.510 |
Why?
|
| Pandemics | 6 | 2023 | 286 | 0.510 |
Why?
|
| Glycated Hemoglobin A | 11 | 2017 | 215 | 0.510 |
Why?
|
| Language | 2 | 2015 | 52 | 0.510 |
Why?
|
| Attitude to Health | 1 | 2017 | 159 | 0.510 |
Why?
|
| African Americans | 6 | 2017 | 465 | 0.500 |
Why?
|
| Postnatal Care | 2 | 2014 | 21 | 0.500 |
Why?
|
| Exercise Therapy | 1 | 2016 | 71 | 0.490 |
Why?
|
| Managed Care Programs | 8 | 2017 | 313 | 0.480 |
Why?
|
| Proteinuria | 1 | 2014 | 26 | 0.450 |
Why?
|
| Social Identification | 1 | 2013 | 7 | 0.440 |
Why?
|
| Registries | 10 | 2012 | 470 | 0.440 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 11 | 0.440 |
Why?
|
| Aged, 80 and over | 13 | 2017 | 1927 | 0.430 |
Why?
|
| Patient Selection | 1 | 2015 | 190 | 0.430 |
Why?
|
| Risk Assessment | 6 | 2019 | 1106 | 0.430 |
Why?
|
| Adiponectin | 1 | 2013 | 23 | 0.430 |
Why?
|
| Asthma | 2 | 2023 | 385 | 0.430 |
Why?
|
| Retrospective Studies | 18 | 2023 | 2471 | 0.420 |
Why?
|
| Employee Incentive Plans | 1 | 2013 | 4 | 0.410 |
Why?
|
| Occupational Health Services | 1 | 2013 | 15 | 0.410 |
Why?
|
| Sex Ratio | 1 | 2012 | 2 | 0.410 |
Why?
|
| Body Weight | 4 | 2020 | 226 | 0.390 |
Why?
|
| Colorectal Neoplasms | 3 | 2013 | 616 | 0.390 |
Why?
|
| Sex Characteristics | 4 | 2007 | 69 | 0.380 |
Why?
|
| Biomarkers | 6 | 2020 | 312 | 0.370 |
Why?
|
| Referral and Consultation | 2 | 2012 | 165 | 0.360 |
Why?
|
| Hyperbilirubinemia | 3 | 2008 | 9 | 0.360 |
Why?
|
| Treatment Outcome | 8 | 2017 | 1254 | 0.360 |
Why?
|
| Minority Groups | 3 | 2022 | 101 | 0.360 |
Why?
|
| Child, Preschool | 9 | 2023 | 1417 | 0.350 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 260 | 0.340 |
Why?
|
| Neoplasms | 2 | 2015 | 442 | 0.340 |
Why?
|
| Prenatal Diagnosis | 1 | 2010 | 18 | 0.340 |
Why?
|
| Lipids | 3 | 2016 | 82 | 0.340 |
Why?
|
| Cholesterol | 5 | 2012 | 106 | 0.340 |
Why?
|
| Proportional Hazards Models | 7 | 2013 | 710 | 0.330 |
Why?
|
| Fasting | 7 | 2014 | 50 | 0.330 |
Why?
|
| Fatty Acids, Omega-3 | 2 | 2019 | 22 | 0.320 |
Why?
|
| Motivational Interviewing | 2 | 2021 | 33 | 0.310 |
Why?
|
| Pneumonia | 1 | 2009 | 51 | 0.310 |
Why?
|
| Puberty | 2 | 2022 | 58 | 0.310 |
Why?
|
| Time Factors | 9 | 2013 | 1095 | 0.310 |
Why?
|
| Prediabetic State | 3 | 2019 | 56 | 0.300 |
Why?
|
| Health Surveys | 6 | 2017 | 260 | 0.290 |
Why?
|
| Gestational Age | 3 | 2020 | 116 | 0.290 |
Why?
|
| Environmental Pollutants | 2 | 2023 | 48 | 0.280 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 196 | 0.280 |
Why?
|
| Electronic Mail | 2 | 2019 | 51 | 0.280 |
Why?
|
| Maternal Exposure | 4 | 2023 | 62 | 0.280 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 956 | 0.270 |
Why?
|
| Cluster Analysis | 2 | 2018 | 90 | 0.270 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2006 | 16 | 0.270 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2022 | 36 | 0.260 |
Why?
|
| Myocardial Infarction | 4 | 2003 | 234 | 0.260 |
Why?
|
| Infant | 7 | 2023 | 1199 | 0.260 |
Why?
|
| Outcome Assessment (Health Care) | 3 | 2015 | 227 | 0.260 |
Why?
|
| Glyburide | 2 | 2022 | 7 | 0.260 |
Why?
|
| Bayes Theorem | 2 | 2023 | 72 | 0.250 |
Why?
|
| Health Behavior | 4 | 2022 | 360 | 0.250 |
Why?
|
| Myocardial Ischemia | 1 | 2004 | 24 | 0.230 |
Why?
|
| Antihypertensive Agents | 2 | 2009 | 159 | 0.230 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 327 | 0.220 |
Why?
|
| Cholesterol, LDL | 3 | 2007 | 119 | 0.220 |
Why?
|
| Educational Status | 5 | 2021 | 198 | 0.220 |
Why?
|
| Counseling | 3 | 2019 | 187 | 0.220 |
Why?
|
| Stress, Psychological | 3 | 2022 | 140 | 0.210 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2003 | 14 | 0.210 |
Why?
|
| Alkanesulfonic Acids | 1 | 2023 | 3 | 0.210 |
Why?
|
| Directive Counseling | 2 | 2014 | 25 | 0.210 |
Why?
|
| Hypersensitivity | 1 | 2023 | 18 | 0.210 |
Why?
|
| Phenol | 1 | 2022 | 4 | 0.210 |
Why?
|
| Fluorocarbons | 1 | 2023 | 13 | 0.210 |
Why?
|
| Progestins | 1 | 2003 | 25 | 0.210 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 23 | 0.200 |
Why?
|
| Estrogens | 1 | 2003 | 61 | 0.200 |
Why?
|
| Phenols | 1 | 2022 | 34 | 0.200 |
Why?
|
| Quality of Health Care | 1 | 2004 | 276 | 0.200 |
Why?
|
| Child Abuse | 1 | 2023 | 44 | 0.200 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 212 | 0.200 |
Why?
|
| Triglycerides | 4 | 2012 | 89 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2014 | 215 | 0.190 |
Why?
|
| Academic Success | 1 | 2021 | 4 | 0.190 |
Why?
|
| Linear Models | 3 | 2016 | 229 | 0.180 |
Why?
|
| Motor Activity | 2 | 2014 | 212 | 0.180 |
Why?
|
| Awards and Prizes | 1 | 2020 | 9 | 0.180 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2010 | 26 | 0.180 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2020 | 58 | 0.170 |
Why?
|
| Motivation | 1 | 2021 | 130 | 0.170 |
Why?
|
| Virtual Reality | 1 | 2020 | 1 | 0.170 |
Why?
|
| Animals | 2 | 2020 | 262 | 0.170 |
Why?
|
| San Francisco | 1 | 2020 | 64 | 0.170 |
Why?
|
| Progesterone | 1 | 2020 | 5 | 0.170 |
Why?
|
| Workplace | 1 | 2020 | 30 | 0.170 |
Why?
|
| Prolactin | 1 | 2020 | 4 | 0.170 |
Why?
|
| Comorbidity | 2 | 2020 | 590 | 0.170 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 8 | 0.170 |
Why?
|
| Ideal Body Weight | 1 | 2020 | 10 | 0.170 |
Why?
|
| Diet | 2 | 2014 | 367 | 0.170 |
Why?
|
| Autism Spectrum Disorder | 1 | 2023 | 165 | 0.170 |
Why?
|
| Likelihood Functions | 1 | 2020 | 45 | 0.170 |
Why?
|
| Thinness | 1 | 2020 | 32 | 0.170 |
Why?
|
| Phospholipids | 1 | 2019 | 3 | 0.160 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2019 | 3 | 0.160 |
Why?
|
| Blood Pressure | 5 | 2012 | 300 | 0.160 |
Why?
|
| Patient Compliance | 4 | 2009 | 299 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2019 | 31 | 0.160 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2019 | 11 | 0.160 |
Why?
|
| Heart Diseases | 2 | 2001 | 75 | 0.160 |
Why?
|
| Morbidity | 1 | 1999 | 59 | 0.160 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 397 | 0.160 |
Why?
|
| Child Health | 1 | 2019 | 35 | 0.160 |
Why?
|
| Disabled Persons | 1 | 1999 | 35 | 0.160 |
Why?
|
| Blood Glucose Self-Monitoring | 4 | 2003 | 46 | 0.160 |
Why?
|
| Program Development | 1 | 2019 | 68 | 0.160 |
Why?
|
| Body Constitution | 2 | 1998 | 41 | 0.160 |
Why?
|
| African Continental Ancestry Group | 2 | 2017 | 162 | 0.160 |
Why?
|
| Cardiovascular System | 1 | 2018 | 4 | 0.150 |
Why?
|
| Healthy Aging | 1 | 2018 | 8 | 0.150 |
Why?
|
| Child Development | 2 | 2023 | 53 | 0.150 |
Why?
|
| Mass Screening | 3 | 2013 | 667 | 0.150 |
Why?
|
| Probability | 3 | 2007 | 78 | 0.150 |
Why?
|
| Prognosis | 3 | 2020 | 613 | 0.140 |
Why?
|
| Infertility, Female | 2 | 2011 | 12 | 0.140 |
Why?
|
| Family Health | 1 | 2017 | 44 | 0.140 |
Why?
|
| Maternal Age | 1 | 2017 | 77 | 0.140 |
Why?
|
| Research Design | 3 | 2016 | 372 | 0.140 |
Why?
|
| Persuasive Communication | 1 | 2017 | 3 | 0.140 |
Why?
|
| Maternal Behavior | 1 | 2017 | 13 | 0.140 |
Why?
|
| Infant, Low Birth Weight | 2 | 2012 | 34 | 0.140 |
Why?
|
| Sports | 1 | 2017 | 21 | 0.140 |
Why?
|
| Cholesterol, HDL | 1 | 1997 | 81 | 0.140 |
Why?
|
| Focus Groups | 1 | 2017 | 146 | 0.140 |
Why?
|
| Anxiety | 3 | 2022 | 152 | 0.130 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 30 | 0.130 |
Why?
|
| Social Environment | 1 | 2017 | 87 | 0.130 |
Why?
|
| Reminder Systems | 1 | 2017 | 80 | 0.130 |
Why?
|
| Metformin | 2 | 2015 | 58 | 0.130 |
Why?
|
| Smoking | 5 | 2015 | 483 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 371 | 0.130 |
Why?
|
| Sex Factors | 6 | 2011 | 639 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 243 | 0.130 |
Why?
|
| Dehydroepiandrosterone | 1 | 1996 | 6 | 0.130 |
Why?
|
| Aging | 1 | 1997 | 163 | 0.130 |
Why?
|
| Mexican Americans | 2 | 2013 | 45 | 0.130 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2016 | 90 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2011 | 355 | 0.130 |
Why?
|
| Recurrence | 3 | 2011 | 189 | 0.130 |
Why?
|
| Mass Media | 1 | 2015 | 17 | 0.130 |
Why?
|
| Waist Circumference | 2 | 2013 | 39 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2017 | 265 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2016 | 62 | 0.120 |
Why?
|
| Program Evaluation | 2 | 2013 | 222 | 0.120 |
Why?
|
| Carcinoma | 1 | 2015 | 22 | 0.120 |
Why?
|
| Hyperinsulinism | 1 | 1994 | 10 | 0.120 |
Why?
|
| Smoking Cessation | 1 | 2016 | 193 | 0.120 |
Why?
|
| Age Factors | 6 | 2016 | 918 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2009 | 324 | 0.120 |
Why?
|
| Postmenopause | 1 | 1996 | 243 | 0.120 |
Why?
|
| Lactation | 2 | 2011 | 53 | 0.110 |
Why?
|
| Diabetic Nephropathies | 2 | 2006 | 26 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2013 | 103 | 0.110 |
Why?
|
| Homeostasis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Liver | 1 | 2014 | 33 | 0.110 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 47 | 0.110 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2014 | 86 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2014 | 38 | 0.110 |
Why?
|
| Insulin Glargine | 1 | 2013 | 9 | 0.110 |
Why?
|
| Adiposity | 1 | 2014 | 66 | 0.110 |
Why?
|
| Reference Values | 4 | 2003 | 93 | 0.110 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2013 | 6 | 0.110 |
Why?
|
| Financing, Personal | 1 | 2003 | 18 | 0.110 |
Why?
|
| Osteoarthritis, Knee | 1 | 2013 | 11 | 0.100 |
Why?
|
| Psychometrics | 1 | 2013 | 122 | 0.100 |
Why?
|
| State Health Plans | 1 | 2013 | 33 | 0.100 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2013 | 13 | 0.100 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2013 | 16 | 0.100 |
Why?
|
| Cost of Illness | 1 | 2003 | 94 | 0.100 |
Why?
|
| Medical Records | 2 | 2004 | 97 | 0.100 |
Why?
|
| Models, Organizational | 1 | 2013 | 54 | 0.100 |
Why?
|
| Age Distribution | 2 | 2004 | 246 | 0.100 |
Why?
|
| Professional-Patient Relations | 1 | 2013 | 46 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 9 | 0.100 |
Why?
|
| Job Description | 1 | 1992 | 1 | 0.100 |
Why?
|
| Specialties, Nursing | 1 | 1992 | 1 | 0.100 |
Why?
|
| Multivariate Analysis | 6 | 2015 | 561 | 0.100 |
Why?
|
| Technology Assessment, Biomedical | 1 | 1992 | 6 | 0.100 |
Why?
|
| Nurse Clinicians | 1 | 1992 | 3 | 0.100 |
Why?
|
| Parity | 2 | 2011 | 74 | 0.100 |
Why?
|
| Preventive Health Services | 1 | 2003 | 151 | 0.090 |
Why?
|
| Bursa, Synovial | 1 | 2011 | 1 | 0.090 |
Why?
|
| Rotator Cuff | 1 | 2011 | 1 | 0.090 |
Why?
|
| Tendon Injuries | 1 | 2011 | 2 | 0.090 |
Why?
|
| Shoulder Joint | 1 | 2011 | 5 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2012 | 123 | 0.090 |
Why?
|
| Colonoscopy | 3 | 2008 | 253 | 0.090 |
Why?
|
| Bilirubin | 2 | 2008 | 30 | 0.090 |
Why?
|
| Fertilization | 1 | 2011 | 3 | 0.090 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 27 | 0.090 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2011 | 11 | 0.090 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 249 | 0.090 |
Why?
|
| Socioeconomic Factors | 5 | 2019 | 626 | 0.090 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 387 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2010 | 95 | 0.080 |
Why?
|
| Adenoma | 1 | 2010 | 94 | 0.080 |
Why?
|
| Social Class | 2 | 2021 | 121 | 0.080 |
Why?
|
| Group Practice | 1 | 2008 | 24 | 0.080 |
Why?
|
| Health Status | 2 | 2021 | 299 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2009 | 185 | 0.070 |
Why?
|
| Residence Characteristics | 1 | 2010 | 248 | 0.070 |
Why?
|
| Systole | 1 | 2007 | 22 | 0.070 |
Why?
|
| Colonic Polyps | 1 | 2007 | 35 | 0.070 |
Why?
|
| Depression | 2 | 2022 | 504 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 158 | 0.070 |
Why?
|
| Androgens | 1 | 2007 | 13 | 0.070 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 12 | 0.070 |
Why?
|
| Perception | 1 | 2007 | 57 | 0.070 |
Why?
|
| Self Concept | 1 | 2007 | 39 | 0.070 |
Why?
|
| Forecasting | 1 | 2007 | 74 | 0.070 |
Why?
|
| Fetal Diseases | 1 | 2006 | 8 | 0.070 |
Why?
|
| Ileostomy | 1 | 2006 | 1 | 0.070 |
Why?
|
| Membranes, Artificial | 1 | 2006 | 1 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 2 | 0.070 |
Why?
|
| Public Health | 1 | 2007 | 81 | 0.070 |
Why?
|
| Italy | 3 | 2003 | 14 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2006 | 16 | 0.070 |
Why?
|
| Colitis | 1 | 2006 | 1 | 0.070 |
Why?
|
| Diverticulum, Colon | 1 | 2006 | 2 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 1998 | 361 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2004 | 26 | 0.050 |
Why?
|
| Obstetric Labor, Premature | 1 | 2003 | 9 | 0.050 |
Why?
|
| DDT | 1 | 2003 | 3 | 0.050 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2003 | 4 | 0.050 |
Why?
|
| Fertility | 1 | 2003 | 9 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 1994 | 80 | 0.050 |
Why?
|
| Insecticides | 1 | 2003 | 7 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2003 | 17 | 0.050 |
Why?
|
| Echocardiography | 1 | 2003 | 32 | 0.050 |
Why?
|
| Receptor, Insulin | 2 | 1993 | 6 | 0.050 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 18 | 0.050 |
Why?
|
| Parturition | 1 | 2022 | 9 | 0.050 |
Why?
|
| Supervised Machine Learning | 1 | 2022 | 2 | 0.050 |
Why?
|
| Validation Studies as Topic | 2 | 2013 | 11 | 0.050 |
Why?
|
| Metabolic Syndrome | 1 | 2003 | 81 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 115 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 128 | 0.050 |
Why?
|
| Accelerometry | 1 | 2022 | 39 | 0.050 |
Why?
|
| Sleep | 1 | 2022 | 58 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2002 | 13 | 0.050 |
Why?
|
| Menarche | 1 | 2022 | 28 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 85 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 79 | 0.050 |
Why?
|
| Mothers | 2 | 2019 | 106 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 137 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 90 | 0.050 |
Why?
|
| Arteriosclerosis | 1 | 1981 | 20 | 0.050 |
Why?
|
| Heart Failure | 2 | 2004 | 398 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2001 | 83 | 0.050 |
Why?
|
| Caregivers | 1 | 2022 | 128 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 161 | 0.040 |
Why?
|
| International Cooperation | 1 | 2010 | 15 | 0.040 |
Why?
|
| Nicotinic Acids | 1 | 1979 | 1 | 0.040 |
Why?
|
| Markov Chains | 1 | 1999 | 22 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2010 | 74 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 1999 | 46 | 0.040 |
Why?
|
| Genomic Imprinting | 1 | 1999 | 2 | 0.040 |
Why?
|
| Transportation of Patients | 1 | 1979 | 4 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2004 | 223 | 0.040 |
Why?
|
| Europe | 1 | 1998 | 42 | 0.040 |
Why?
|
| Social Support | 1 | 1999 | 204 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 1997 | 7 | 0.040 |
Why?
|
| Geography, Medical | 1 | 2017 | 4 | 0.040 |
Why?
|
| Environmental Exposure | 2 | 2011 | 117 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 52 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 7 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 15 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 1996 | 5 | 0.030 |
Why?
|
| Hip | 1 | 1996 | 9 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1995 | 7 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1995 | 159 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2014 | 64 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 416 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2015 | 175 | 0.030 |
Why?
|
| Glutamine | 1 | 1993 | 2 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2003 | 5 | 0.030 |
Why?
|
| Reoperation | 1 | 2013 | 30 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2013 | 68 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 90 | 0.030 |
Why?
|
| Epidemiologic Studies | 1 | 2012 | 29 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 204 | 0.020 |
Why?
|
| Genes | 1 | 1992 | 1 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1992 | 1 | 0.020 |
Why?
|
| Advertising as Topic | 1 | 1992 | 23 | 0.020 |
Why?
|
| Infant Food | 1 | 2011 | 8 | 0.020 |
Why?
|
| Research | 1 | 1992 | 64 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2011 | 8 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 32 | 0.020 |
Why?
|
| Poverty | 1 | 2013 | 166 | 0.020 |
Why?
|
| Mutation | 1 | 1992 | 131 | 0.020 |
Why?
|
| Genotype | 1 | 2012 | 227 | 0.020 |
Why?
|
| Rotator Cuff Injuries | 1 | 2011 | 2 | 0.020 |
Why?
|
| Arthroscopy | 1 | 2011 | 2 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2011 | 5 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 5 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 237 | 0.020 |
Why?
|
| Drug Prescriptions | 1 | 1992 | 151 | 0.020 |
Why?
|
| Preconception Injuries | 1 | 2011 | 1 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2007 | 381 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 2011 | 5 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2013 | 164 | 0.020 |
Why?
|
| New England | 1 | 2010 | 13 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 107 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 379 | 0.020 |
Why?
|
| Physicians, Women | 1 | 2009 | 10 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 39 | 0.020 |
Why?
|
| Trust | 1 | 2009 | 30 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2012 | 377 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2009 | 53 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2009 | 40 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 448 | 0.020 |
Why?
|
| Nicardipine | 1 | 1989 | 1 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 179 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 137 | 0.020 |
Why?
|
| Ligands | 1 | 2008 | 6 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 1988 | 1 | 0.020 |
Why?
|
| Glycemic Index | 1 | 2008 | 20 | 0.020 |
Why?
|
| Asphyxia | 1 | 1988 | 3 | 0.020 |
Why?
|
| Sulfonylurea Compounds | 1 | 2007 | 25 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2007 | 65 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 36 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2007 | 35 | 0.020 |
Why?
|
| Bias | 1 | 2007 | 103 | 0.020 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2007 | 102 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 4 | 0.020 |
Why?
|
| Tissue Adhesions | 1 | 2006 | 2 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2006 | 10 | 0.020 |
Why?
|
| Albuminuria | 1 | 2006 | 38 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 60 | 0.020 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2006 | 53 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2006 | 86 | 0.020 |
Why?
|
| Phototherapy | 1 | 2005 | 22 | 0.020 |
Why?
|
| Family Planning Services | 1 | 2005 | 19 | 0.010 |
Why?
|
| Maternal Health Services | 1 | 2005 | 11 | 0.010 |
Why?
|
| Pre-Eclampsia | 1 | 2005 | 44 | 0.010 |
Why?
|
| Amputation | 1 | 2002 | 11 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2004 | 241 | 0.010 |
Why?
|
| Infection | 1 | 2001 | 17 | 0.010 |
Why?
|
| New York | 1 | 1981 | 19 | 0.010 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 1981 | 7 | 0.010 |
Why?
|
| Urban Health | 1 | 1981 | 38 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 151 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 262 | 0.010 |
Why?
|
| Endarteritis | 1 | 1979 | 1 | 0.010 |
Why?
|
| Tolbutamide | 1 | 1979 | 3 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1979 | 2 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1999 | 7 | 0.010 |
Why?
|
| Fathers | 1 | 1999 | 10 | 0.010 |
Why?
|
| Stroke | 1 | 2002 | 316 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2001 | 314 | 0.010 |
Why?
|
| Communication | 1 | 2000 | 191 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1979 | 111 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 17 | 0.010 |
Why?
|
| Hospitalization | 1 | 2001 | 805 | 0.010 |
Why?
|
| Carcinoma, Lobular | 1 | 1994 | 10 | 0.010 |
Why?
|
| Cytochalasin B | 1 | 1993 | 1 | 0.010 |
Why?
|
| Deoxyglucose | 1 | 1993 | 1 | 0.010 |
Why?
|
| Glycogen Synthase | 1 | 1993 | 1 | 0.010 |
Why?
|
| Phosphotransferases | 1 | 1993 | 1 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 2 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1993 | 4 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1993 | 12 | 0.010 |
Why?
|
| Point Mutation | 1 | 1993 | 6 | 0.010 |
Why?
|
| Fibroblasts | 1 | 1993 | 4 | 0.010 |
Why?
|
| Menopause | 1 | 1994 | 70 | 0.010 |
Why?
|
| Glucose | 1 | 1993 | 32 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1994 | 53 | 0.010 |
Why?
|
| Aminobutyrates | 1 | 1993 | 18 | 0.010 |
Why?
|
| National Health Programs | 1 | 1992 | 10 | 0.010 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1992 | 1 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 5 | 0.010 |
Why?
|
| Exons | 1 | 1992 | 8 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1992 | 10 | 0.010 |
Why?
|
| Base Sequence | 1 | 1992 | 19 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1992 | 7 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 18 | 0.010 |
Why?
|
| Heterozygote | 1 | 1992 | 26 | 0.010 |
Why?
|
| DNA | 1 | 1992 | 22 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 49 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1994 | 173 | 0.010 |
Why?
|
| Alleles | 1 | 1992 | 85 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1992 | 304 | 0.010 |
Why?
|
| Genetic Testing | 1 | 1992 | 74 | 0.010 |
Why?
|
| Data Collection | 1 | 1992 | 252 | 0.010 |
Why?
|
| Heart Rate | 1 | 1989 | 41 | 0.000 |
Why?
|
| Animals, Newborn | 1 | 1988 | 1 | 0.000 |
Why?
|
| Brain Chemistry | 1 | 1988 | 1 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 4 | 0.000 |
Why?
|
| Rats | 1 | 1988 | 30 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 37 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1988 | 19 | 0.000 |
Why?
|